FDA approves BAVENCIO in association with axiathani as a first-line treatment for patients with advanced renal cell carcinoma (RCC)

recently, the United StatesThe FDA(http://approved BAVENCIO (Avelumab) in conjunction with INLYTA as a first-line treatment for patients with advanced renal cell carcinoma (RCC)this is also the first time the FDA has approved PD-L1 immunotherapy as a combination of treatments for patients with advanced kidney cancerAbout BAVENCIO
BAVENCIO is a PD-L1 inhibitor and is a high-profile class of cancer immunotherapyThe drug has been approved by the FDA for the treatment of metastatic merkel cell carcinoma (MCC) and localized advanced or metastatic urinary disease (mUC) patients who have undergone chemotherapyThe approval of a new combination of BAVENCIO and axioinib provides patients with advanced kidney cancer with much-needed treatment optionsThe approval was based on the results of the phase III ClinicalTrial(http://of JAVELIN Renal 101, which included 886 patients with advanced renal cell carcinoma who had not been treated and did not take into account PD-L1 expressionThe results showed thatcompared to sconeinib, combined therapy reduced the risk of progression or death in patients with advanced kidney cancer by 31%;Patients in the combined therapy group were 2 times more effective than the sconetinib group (51.4% VS25.7%)
;Combination therapy extends the patient's progression-free survival (PFS) by 5.4 months (13.8:8.4 months);In terms of safety, the co-treatment group had a lower percentage of side effects